TCGA-4Z-AA7W-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 27.59526938
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.580
- ALLOGRAFT_REJECTION+0.570
- INFLAMMATORY_RESPONSE+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
- IL6_JAK_STAT3_SIGNALING+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- COMPLEMENT+0.330
- OXIDATIVE_PHOSPHORYLATION+0.280
- IL2_STAT5_SIGNALING+0.250
Top 10 suppressed
- TGF_BETA_SIGNALING-0.330
- HEDGEHOG_SIGNALING-0.320
- UV_RESPONSE_DN-0.320
- ANGIOGENESIS-0.310
- MITOTIC_SPINDLE-0.310
- PROTEIN_SECRETION-0.290
- WNT_BETA_CATENIN_SIGNALING-0.200
- HEME_METABOLISM-0.130
- ANDROGEN_RESPONSE-0.120
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.860 |
| 2 | SRR8518165 | — | C | 0.838 |
| 3 | SRR35579807 | — | C | 0.836 |
| 4 | TCGA-BT-A42F-01A-11R-A23W-07 | — | — | 0.832 |
| 5 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.827 |
| 6 | SRR5088870 | — | — | 0.824 |
| 7 | SRR8392897 | — | cohortSQ2 | 0.822 |
| 8 | 20080305.TNBC | — | D | 0.818 |
| 9 | TCGA-F7-A620-01A-11R-A28V-07 | — | — | 0.817 |
| 10 | ERR2208914 | — | — | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |